Key aspects of ETI's business model are:

	Diverse Team of Technical Business Managers ETI Business Managers have expertise ranging from Chemistry and Chemical Engineering to Biochemistry, Biomedical Science, Clinical Diagnostics, Medicine, and Molecular Biology. Many ETI and ETI portfolio company employees hold advanced science degrees.
	Early Partnering With Industry Leaders Rather than applying large capital outlay towards fully developing a single application, we spend only a portion of that capital to bring multiple proofs of concept to market leaders, who fund completion of the development. ETI acts as an extension of early-phase research for industry partners, filling companies' product pipelines.
	Stringent Technology Selection Criteria and Portfolio Synergy ETI selects technologies that are: Platforms, with multiple market applications Already significantly developed through academic funding Synergistic to our current portfolio in immunology, glycobiology, clinical diagnostics, drug delivery, and biomaterials Strong potential for intellectual property Potential for short-term revenue and also eventual revenue to the partner of over $500,000,000 annually Led by scientists with business acumen and a sense of entrepreneurship
	Building Liquidity/Exit Strategy into a Deal We are not only interested in building the value of each portfolio company, but also interested in delivering frequent liquidity events to our investors. By engineering liquidity events into each partner deal, we empower a business strategy that is able to rapidly move funds to new opportunities or to more lucrative deals.